Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders

T Bhattacharya, GAB Soares, H Chopra, MM Rahman… - Materials, 2022 - mdpi.com
The strategies involved in the development of therapeutics for neurodegenerative disorders
are very complex and challenging due to the existence of the blood-brain barrier (BBB), a …

Recent advances on the improvement of quercetin bioavailability

K Kandemir, M Tomas, DJ McClements… - Trends in Food Science & …, 2022 - Elsevier
Background Natural antioxidants, such as polyphenols, are finding increasing application in
functional foods designed to improve human health, wellbeing, and performance. Quercetin …

Relationship between amyloid-β deposition and blood–brain barrier dysfunction in Alzheimer's disease

D Wang, F Chen, Z Han, Z Yin, X Ge… - Frontiers in Cellular …, 2021 - frontiersin.org
Amyloid-β (Aβ) is the predominant pathologic protein in Alzheimer's disease (AD). The
production and deposition of Aβ are important factors affecting AD progression and …

Neuropharmacological effects of quercetin: a literature-based review

MS Islam, C Quispe, R Hossain, MT Islam… - Frontiers in …, 2021 - frontiersin.org
Quercetin (QUR) is a natural bioactive flavonoid that has been lately very studied for its
beneficial properties in many pathologies. Its neuroprotective effects have been …

Antioxidant therapy in oxidative stress-induced neurodegenerative diseases: Role of nanoparticle-based drug delivery systems in clinical translation

A Ashok, SS Andrabi, S Mansoor, Y Kuang, BK Kwon… - Antioxidants, 2022 - mdpi.com
Free radicals are formed as a part of normal metabolic activities but are neutralized by the
endogenous antioxidants present in cells/tissue, thus maintaining the redox balance. This …

[HTML][HTML] Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases

MI Teixeira, CM Lopes, MH Amaral, PC Costa - Colloids and Surfaces B …, 2023 - Elsevier
The blood-brain barrier (BBB) restricts the access of therapeutic agents to the brain,
complicating the treatment of neurological diseases, such as Alzheimer's disease (AD) …

Improving drug delivery for Alzheimer's disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels

S Cunha, B Forbes, JM Sousa Lobo… - International journal of …, 2021 - Taylor & Francis
Current treatments for Alzheimer's disease (AD) attenuate the progression of symptoms and
aim to improve the patient's quality of life. Licensed medicines are mostly for oral …

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges

A Cano, P Turowski, M Ettcheto, JT Duskey… - Journal of …, 2021 - Springer
Increasing life expectancy has led to an aging population, which has consequently
increased the prevalence of dementia. Alzheimer's disease (AD), the most common form of …

Nanoformulations to enhance the bioavailability and physiological functions of polyphenols

B Yang, Y Dong, F Wang, Y Zhang - Molecules, 2020 - mdpi.com
Polyphenols are micronutrients that are widely present in human daily diets. Numerous
studies have demonstrated their potential as antioxidants and anti-inflammatory agents, and …

Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer's disease

S Ghosh, B Sachdeva, P Sachdeva, V Chaudhary… - Carbon Letters, 2022 - Springer
Alzheimer's disease (AD) is one of the most common forms of dementia, affecting more than
50 million people globally. The onset of AD is linked to age, smoking, obesity …